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ABSTRACT
Objectives: There is growing evidence that Treg cell infiltration into the cancer nest is associated with poor prognosis. How-
ever, the Treg cell population in the peripheral blood may change when a different type of anticancer therapy is applied. 
Since Treg cells may support tumor growth by enhancing the suppressive profile of the cancer microenvironment, the 
assessment of Treg cells can bring to light important information regarding prognosis. Thus we decided to analyze the 
Treg cell population in the peripheral blood in relation to long-term outcomes in the group of patients with ovarian cancer.
Material and methods: The 80 patients included in the study were treated surgically followed by chemiotherapy for ovar-
ian cancer between October 2010 through May 2011.The peripheral blood samples from the patients were collected directly 
prior to chemotherapy. Information on any patients who died was retrieved from the database of the Cuiavia-Pomerania 
Regional Office of the National Health System of Poland. CD4+CD25+FOXP3+ lymphocytes T were assed by flow cytometry. 
We have analyzed the long term outcomes of treatment regarding to the level of Treg cells in peripheral blood.
Results: We found that patients with serous adenocarcinomas had significantly higher Treg levels compared to those 
patients with non-serous types. Patients who had a higher percentage of Treg cells within the CD4+ cell population prior 
to the beginning of the treatment had worse long-term outcomes from the applied therapy.
Conclusions: The assessment of Treg levels prior to the start of chemotherapy is clinically useful and may predict overall 
survival in ovarian cancer patients.
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INTRODUCTION
Regulatory T cells (Tregs) represent 1.3% of the total 
CD4+ cell population [1]. Tregs are distinguished from other 
T cells by the expression of the transcription factor Forkhead 
box protein 3 (FoxP3) [2]. The transcription factor FoxP3 is 
crucial for suppressing the activity of Treg cells; it directly sup-
presses IL-2 gene transcription and upregulates CTLA-4 and 
IL-2 receptor α-chain gene transcription [3]. The popula-
tion of Treg cells consists of naïve (nTreg, FoxP3 low, and 
CD45RA+) and effector (FoxP3 high and CD45RA) Treg cells 
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[4]. These cell scan both suppress the activation of immune 
system cells and block already activated T lymphocytes. It is 
well known that Treg cells can suppress most immune cells 
including CD4+ and CD8+ lymphocytes, B cells, NK cells, 
NKT cells, APCs, monocytes, macrophages, and DCs [2]. 
Regulatory T cells (Tregs) are an important contributor 
to the immunosuppressive tumor microenvironment and, 
consequently, they play a critical role in the suppression of 
inflammation and the process of cancer cell evasion of the 
host immune surveillance [5].
Recently, it has been proven that in patients with some-
types of cancers (for example, breast [6], lung [7], urinary 
bladder [8], and ovarian cancers [9, 10] the Treg cell sub-
population size correlates withan advanced stage of cancer. 
However, there is no such correlation with the histological 
tumor type, for instance, squamous vs adenocarcinoma 
in patients with lung cancer [7] and mucinous vs serous 
adenocarcinoma in patients with ovarian cancer [10]. Wu 
et al. demonstrated differences in the Treg population size 
which correlated with whether the tumor was malignant or 
benign. The level of Treg cells in the peripheral blood was 
significantly higher in the patients with ovarian cancers 
compared to those with benign ovarian tumors [10]. Curiel 
et al. [11] observed that the infiltration of the ovarian can-
cer nest by Treg cells has a negative impact on prognosis, 
and Zhou et al. [4] showed that the Il-10 secreted by TAMs 
increased the number of Treg cells through the activation 
of FoxP3 during T-cell differentiation and promotes tumor 
progression. Recently, it has been demonstrated that the 
monoclonal antibodies against CTLA4 and PLD-1, proteins 
present on the Treg cell membrane, are clinically useful in 
therapy for patients with various types of cancers, and both 
are key components of Treg cell activity [1].
On the other hand, the Treg cell population in the pe-
ripheral blood may change when a different type of anti-
cancer therapy is applied. Previous studies have shown that 
radical cytoreductive surgery in ovarian cancer patients was 
associated with a significant decline in the Treg population 
analyzed in the peripheral blood [12]. Wu et al. observed 
a significant fall in the postoperative level of Treg cells in 
comparison to the preoperative level. The lowest concentra-
tion of Treg cells was observed 30 days after surgery [10]. 
Chen et al. [7] proved that the level of Treg cells dropped 
significantly following lung cancer surgery. The application 
of the radiochemotherapy has also been proven to influ-
ence the Treg cell level. Wang et al. demonstrated that in 
the patients with stages II/III breast cancer the percentage 
of the Treg cells fell significantly following the six cycles of 
chemotherapy [6]. Shaobin et al. [13] observed that the 
radiofrequency ablation in lung cancer patients decreased 
the percentage of Treg cells within CD4+ lymphocytes in 
the peripheral blood.
However, cancer treatment is a complex process con-
sisting mostly of classic chemotherapy, radiotherapy, and 
surgery. Moreover, it has been demonstrated that surgery 
and chemoradiotherapy influence the Treg cell population 
and enhance the antitumor immune response. They inter-
rupt the stabilizing pathways of Treg cells, making them 
more sensitive to the immunotherapy. Further studies on 
this subject are needed to elucidate the emerging pathways 
of Treg stabilization and destabilization and could reveal 
new molecular targets for therapy [14].
Since Treg cells may support tumor growth by enhanc-
ing the suppressive profile of the cancer microenvironment, 
the assessment of Treg cells can bring to light important 
information regarding prognosis. 
There is growing evidence that Treg cell infiltration into 
the cancer nest is associated with poor prognosis. The find-
ings in the literature on this subject are conflicting. For exam-
ple, Curiel et al. [11] demonstrated a correlation between the 
level of Treg cells and both high death hazard and reduced 
survival in a group of ovarian cancer patients. The patients 
with the highest Treg cell infiltration had a 25 times greater 
risk of death compared to the patients with the lowest 
levels of Treg cell infiltration [11]. Mhawech-Fauceglia et al. 
reported that in patients with familial ovarian cancer,the size 
of the Treg cell population was the only significant predictor 
of prognosis. They also proved that high tumor grade corre-
lates with the infiltration of Treg cells [15]. Contrarily, Leffers 
et al. analyzed patients with advanced stage ovarian cancer 
and observed that CD8+ and FoxP4+ Treg infiltration was 
an independent predictor of improved prognosis. Further-
more, the relationship between Treg cell levels and survival 
was analyzed in patients with other types of cancers, includ-
ing breast cancer [16]. By contrast, Noordam et al. found 
no correlation between the overall Treg level and survival. 
However, in this study, when the authors distinguished 
naive from effector Treg cells, they observed that the nTreg 
level corresponded with improved survival [17]. Noordam 
et al. [17] have demonstrated that the number of naïve Treg 
(nTreg) cells in the peripheral blood positively correlates 
with survival in malignant pleural mesothelioma patients. 
Objectives
Thus we decided to analyze the Treg cell population 
in the peripheral blood in relation to long-term outcomes 
in the group of patients with ovarian cancer treated by 
a cytoreductive surgery followed by six courses of a chemo-
therapy based on platins and taxans.
MATERIAL AND METHODS
Study group
The 80 patients included in the study were treated surgi-
cally for ovarian cancer between October 2010 through May 
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2011 in the the Department of Gynecology and Oncology 
of the Lukaszczyk Oncological Center, Bydgoszcz, Poland. 
The median patient age was 58 years (range 35–81). As the 
average age at which a woman goes through menopause in 
Poland is 51 years, women in the study over the age of 51 were 
assessed as postmenopausal. The study included 18 pre-
menopausal and 62 postmenopausal women. All patients 
underwent standard surgical treatment for ovarian cancer. 
Tumors removed during surgery were examined histopatho-
logically and classified according to the WHO criteria.
The study group included 53 high-grade serous ad-
enocarcinomas, 8 mucinous adenocarcinomas, 5 clear cell 
adenocarcinomas, 10 endometrioid adenocarcinomas, and 
4 nondifferentiated adenocarcinomas. Thirty-eight tumors 
were graded as G3, 33 as G2, and 9 as G1 tumors. EOCs were 
classified according to the then-current International Fed-
eration of Gynecology and Obstetrics (FIGO) system. Patients 
were subdivided according to the FIGO stage of the disease 
as follows: 14 stage I patients, 10 stage II patients, 53 stage 
III patients, and 3 patients had disease classified as stage IV.
The study group consisted of 80 samples of the primary 
EOCs. Blood samples from the patients were collected di-
rectly prior to chemotherapy. The samples were collected in 
a serum collection tube. A clot was allowed to form at a room 
temperature for 30–60 minutes. Next, the tube was placed 
on ice for 30 minutes to contract the clot stored at -80°C.
The median follow up for our patients was 1.163 days 
(range 34–3.142 days). Information on any patients who died 
was retrieved from the database of the Cuiavia-Pomerania 
Regional Office of the National Health System of Poland. 
The patient’s consent was obtained in each case. Prior to 
the present study, we also obtained the approval of the 
Jagiellonian University Ethical Committee for our research 
program (DK⁄KB⁄CM⁄0031⁄447⁄2010)
Flow cytometry
The samples for the cytometric analysis of the Treg cell 
population in the whole blood of patients and healthy do-
nors were prepared using Human Regulatory T Cell Staining 
Kit (eBioscience), according to the manufacturer’s instruc-
tions with some minor modifications. To the 100 µL of blood, 
15 µL of CD4 FITC and CD25 PE cocktail, as well 5 µL of 
CD45 APC-Cy7 (Becton Dickinson) was added. After 30 min 
of incubation with mAbs (in the dark at 4°C) the cells were 
washed with Flow Cytometry Staining Buffer, centrifuged 
for 5 min at 350 × g, and then permeabilized with freshly 
prepared Fixation/Permeabilization Buffer (for 40 min in the 
dark at 4°C). Next, the cells were washed twice by adding 1× 
Permeabilization Buffer, blocked by normal rat serum (for 
15 min in the dark at 4°C) and subsequently stained with 
anti-human FoxP3 APC antibody or rat IgG2a κ APC antibody 
(in the case of isotype control) for 35 min in the dark at 4°C. 
After another washing step, the cells were suspended in 
Flow Cytometry Staining Buffer and analyzed using BD FACS 
Canto II flow cytometer and BD FACS Diva Software (Becton 
Dickinson). In each sample, 3 × 104 lymphocytes were col-
lected and gated on SSC × CD45 APC-Cy7 dot-plot. Next, the 
populations of CD4+ FITC, CD25+ PE, and double-positive 
CD4 and CD25 cells were distinguished among the lym-
phocytes. Finally, the gate of FoxP3 positive cells was estab-
lished on CD4+CD25+ subpopulation. For each sample, the 
negative control was performed on the specific-stained cell 
analysis in order to measure autofluorescence and the iso-
type control was performed in order to exclude non-specific 
staining of specific antibodies.
Statistical analysis
The nonparametric Mann-Whitney test was used to 
compare Treg levels according to menopausal status, FIGO 
stage, tumor grade, and the histopathological type of the 
tumor. The correlation with patient age was performed us-
ing the non-parametric Spearman Rank Correlation. Survival 
analyses were conducted using the Kaplan-Meier survival 
curves. The groups for survival analyses were distinguished 
according to median Treg levels. A result was considered 
significant when the P-value was less than 0.05.
RESULTS
The patients with low pre-chemotherapy Treg levels (below 
median [3.7]) have significantly longer overall survival com-
pared to the patients with high (above median) pre-chemo-
therapy Treg levels (1.636 days, range 34–3.142 vs 1.001 days 
35–2.962; P = 0.024). Figure 1 presents the survival curves. No 
correlation between Treg levels and patient age was found 
(R Spearman = -0.001, P = 0.992). Similarly, Treg levels were not 
Figure 1. The comparison of the overall survival curves of the 
patients with low and high pre-chemotherapy Treg levels. Group 1: 
Patients with low (below median [3.7]) pre-chemotherapy Treg levels 
(median survival 1.636 days, range 34–3.142). Group 2: Patients with 
high (above median) pre-chemotherapy Treg levels (median survival 
1,001 days, range 35–2.962; P = 0.024).
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influenced by menopausal status (P = 0.56). Table 1 presents the 
level of Treg cells in correlation to the FIGO stage of the disease.
We found significantly higher pre-chemotherapy Treg 
levels in patients with grade 3 tumors, compared to those with 
G1/2 tumors. Within all of the studied groups, there were no 
differences in Treg levels in relation to the histopathological 
type of the tumor. However, when the Treg levels of patients 
with serous adenocarcinomas and patients with other types 
of ovarian malignancies were compared, there was a statisti-
cally significant difference. Table 1 summarizes the results.
DISCUSSION
We found that patients with serous adenocarcinomas 
had significantly higher Treg levels compared to those pa-
tients with non-serous types. Patients who had a higher 
percentage of Treg cells within the CD4 + cell population 
prior to the beginning of the treatment had worse long-term 
outcomes from the applied therapy.
Many studies [9, 11, 18] have observed the association 
between Treg cells, poor prognosis, and unfavorable disease 
characteristics; however, the findings have conflicted. Curiel et 
al. studied Treg cell levels in ovarian cancer patients, focusing on 
Treg cell infiltration into the tumor nest, and found a correlation 
between Treg cells and both reduced survival and high death 
hazard. Cannioto et al. [9] confirmed the increased frequency 
of Treg cells inthe peripheral blood of ovarian cancer patients 
in comparison to patients with benign tumors and to a healthy 
control group. In a study by Mhawech-Fauceglia et al., high 
tumor grade correlated with the infiltration of Treg cells. More-
over, the size of the Treg cell infiltration was the only significant 
positive prognostic predictor in patients with familial ovar-
ian cancer [15]. Leffers et al. analyzed patients with advanced 
stage ovarian cancer and observed that CD8+ and FoxP3+ T-cell 
intertumoral infiltration was an independent prognostic factor 
of disease-specific survival in ovarian cancer patients. They 
also observed a correlation between the Cd8+/FoxP3+ ratio 
and increased survival [16]. In this study, the Treg cell popula-
tion was assessed through immunohistochemistry in paraffin 
embedded tissue using antiFoxP3 monoclonal antibodies. The 
presence of FoxP3-positive cells was positively associated with 
an advanced stage of the disease. However, poor differentiation 
and advanced stage of the tumor are well-known negative 
prognostic factors. The authors themselves noted that the 
FoxP3 expression is not exclusive to Treg cells and can also be 
present in activated effector T cells CD4+ and CD25- that do 
not have regulation activity [16]. Similarly, more FoxP3+cells 
were present in the poorly differentiated tumors. Moreover, 
the main result of this study was the positive influence of the 
intertumoral CD8+ T cell infiltration on survival. This corre-
spondence linking increased cytotoxic activity of T cells and 
an increased survival accords with the studies of Curiel et al. 
and others [11]. For example, Zhang et al. [19] observed that 
the presence of intertumoral cytotoxic T cells correlated with 
improved clinical outcome and either delayed recurrence or de-
layed death in patients with advanced ovarian carcinoma [19]. 
The high level of CD3+ cytotoxic lymphocytes was proven to 
be linked with an increased expression of interferon-gamma, 
interleukin-2, and lymphocyte-attracting chemokines within 
the cancer nest [19]. Increased immune response linked with 
a depletion of Treg cells from the tumor microenvironment may 
be related to improved long-term outcomes in ovarian cancer 
patients. Treg cells infiltrate a cancer nest, and cancer develop-
ment is related to an increased Treg cell level in the peripheral 
blood, ascites, and a microenvironment of cancer metastases 
such as the omentum [9, 20]. Increasing infiltration of Treg cells 
into a tumor site leads tothe suppression of an anti-cancer im-
mune response in patients with various types of cancers [2]. 
Noordam et al. analyzed the overall Treg cell levels in the pe-
ripheral blood as these were shown to correlate with decreased 
survival in malignant pleural mesothelioma patients. However, 
when they divided the Treg population into naïve and effector 
cells, they observed that nTreg levels corresponded with im-
proved survival rates [17]. Notably, Chung demonstrated that 
CD4+ T cell infiltration in patients with breast cancer is linked 
with improved survival rates, but breast cancer patients with 
a high percentage of FoxP3+/CD8+ within the CD4 + Tcells have 
decreased survival rates. Increasing the FoxP3+/CD4+ ration 
Table 1. Treg levels according to clinicopathological features of 
ovarian cancer disease
Median (range) P — value
Premenopausal women 3.5 (0.3–7.4)
P = 0.56
Postmenopausal women 3.8 (0.1–18.5)
Median (range) P — value
FIGO I 1.95 (0.2–4.5)
P = 0.076
FIGO II 3.2 (0.7–18.5)
FIGO III 4.0 (0.1–10.5)
FIGO IV 5.1 (2.8–7.0)
Median (range) P — value
G1 and G2 2.8 (0.4–18.5)
P = 0.039
G3 4.1 (0.5–9.4)
Median (range) P — value
Serous adenocarcinoma 3.8 (0.1–18.5)
P = 0.033
Others 2.3 (0.3–8.0)
Median (range) P — value
Serous adenocarcinoma 3.8 (0.1–18.5)
P = 0.066
Mucinous adenocarcinoma 1.95 (1.0–4.2)
Endometrioid adenocarcinoma 2.35 (1.2–4.5)
Clear-cell adenocarcinomas 0.3 (0.2–1.1)
Non-differentiated tumors 4.3 (1.1–8.0)
Non-serous adenocarcinoma 2.3 (0.3–8.0)
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of TIL seems to be an independent adverse prognostic factor 
in a hormone receptor positive group of patients, mainly in 
a luminal A subtype of breast cancer [21]. Analyses of patients 
with lung [7], urinary bladder [8] and ovarian cancers [9, 10] 
yielded similar results, confirming the relationship between 
Treg cell population size and cancer stage.
In our study, we analyzed the percentage of Treg cells 
(FoxP3+) in the overall T-cell population (CD4+ and CD25+) 
in the peripheral blood of ovarian cancer patients and found 
that an increased level of FoxP3+, CD4+, and CD25+ cells 
statistically significantly correlated with a worse prognosis. 
Treg cells constitute a dynamic population of cells whose 
activity depends on multiple factors, including cytokines, 
chemokines, and others. Li et al. linked the poor prognosis 
with the fact that the infiltration of Treg cells to the cancer 
nest is associated with increasing transcript levels of IL-
10 and TGFB1. This has been confirmed in ovarian cancer 
patients, among others [5]. High epithelial IL-6 expression 
is linked with worse survival rates in patients with ovar-
ian cancer, and this cytokine is involved in the expansion of 
immune cells (mainly CD4+ cells andTreg cells [22]) in the 
tumor microenvironment [23, 24]. Furthermore, Toker et 
al. demonstrated that the Treg cells that infiltrate the ovar-
ian cancer nest are typified by a distinct surface phenotype 
that differs from the ones found in other types of cancer 
nests. These cells are characterized by an increased expres-
sion of PD-1 and 4-1BB, both of which are associated with 
an increased suppressive capacity [25]. Additionally, Curiel 
et al. reported that, in the later stages of cancer, Treg cells 
seem to have a preference towards tumors and ascites and 
will only rarely accumulate in the draining lymph nodes [11].
Cancer surgery is necessary and life-saving; however, 
the majority of patients develop postoperative recurrence 
and metastases, which constitute the two main causes of 
cancer-related deaths. Rationally combining cancer surgery 
with immunotherapies to improve immune and treatment 
outcomes can transform an immunosuppressive effect into 
a therapeutic opportunity [26]. Various types of anticancer 
drugs have been designed to influence the Treg cell popula-
tion in both thetumor microenvironment and the peripheral 
blood. For instance, it has been proven that Treg cell levels 
decline significantly in the peripheral blood of patients 
treated by radiofrequency ablation for advanced lung can-
cer [13]. Neoadjuvant chemotherapy (NACT) is also associ-
ated with the reduced infiltration of Treg cells in omental 
biopsy for advanced ovarian cancer in a group of patients 
responding to NACT. However, the enhanced immune re-
sponse in the ovarian cancer microenvironment that should 
follow such changes in the Treg cell level is tempered by the 
increased level of PLD-1 and CTLA-4 expression [20].
Depending on the tumor microenvironment profile, the 
suppressor activity of Tregs can be redirected into a pro-in-
flammatory phenotype. The ovarian cancer nest is infiltrated 
by Treg cells [11] that have been found to be of a highly acti-
vated phenotype. Treg cells with strong suppressive activity 
can be found not only in cancer tissue, but also in the periph-
eral blood. Both populations are being extensively studied 
for their potential use in anticancer therapy. On the other 
hand, it is possible to instrumentally evoke and augment an-
titumor immunity in cancer patients by selectively depleting 
eTreg cells [27] (by blocking the chemokine CTLA-4 receptor) 
or by using the monoclonal antibody against the PD-1 recep-
tor. Treg cells express the well-known immune checkpoint 
receptor PD-1, which reportedly marks “exhausted” Treg with 
lower suppressive function [28].
Treg cells are not only responsible for the evasion of 
cancer cells from immune surveillance, but also cooperate 
with other immune cells, including TAMs, which are pre-
dominantly from M2 subgroups [29, 30]. These subgroups 
are responsible for the secretion of TGF-beta and Il-10 that 
support the differentiation of Treg cells [31]. TAM may also 
interact with Treg cells in the tumor microenvironment, 
producing exosomes, such as miRNAs [4]. Targeting these 
exosomes might become a novel treatment for ovarian can-
cer [4]. Monoclonal antibodies against CCR4 are able to 
selectively reduce the Treg cell population. Chemokine axis 
CCL22-CCR4 plays a critical role in the recruitment of Tregs 
through CCR4 receptors that are present on Treg cells. Fur-
thermore, anti-CCR4 mAb supports the efficacy of immu-
notherapy in ovarian cancer patients [27]. 
Cancer surgery is necessary and life-saving; however, the 
majority of patients develop postoperative recurrence and 
metastases, which constitute the main causes of cancer-re-
lated deaths [32]. Rationally combining cancer surgery with 
immunotherapies can transform the immunosuppressive 
effect into a therapeutic opportunity [26].
CONCLUSIONS
In sum, it is well-known that Treg cells may be a key 
component of the immunosuppressive tumor microenviron-
ment that is responsible for tumor cell escape from immune 
surveillance [25]. The assessment of Treg levels prior to the 
start of chemotherapy is clinically useful and may predict 
overall survival in ovarian cancer patients.
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